greeksoup/ stock research
Stock research / United States / ZBH · Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE

Zimmer Biomet Holdings, Inc. (ZBH)

Zimmer Biomet designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic products; bone cement; surgical products; and integrated digital and robotic technologies, all for patients with disorders of, or injuries to, bones, joints or supporting soft tissues. Zimmer Biomet Holdings was incorporated in Delaware in 2001, though the history runs back to 1927 and predecessor Zimmer Manufacturing Company in Warsaw, Indiana. It was spun off from its former parent on 6 August 2001, and in 2015 acquired the parent of Biomet and changed its name from Zimmer Holdings. There were approximately 17,000 employees worldwide at the end of 2025, about 7,000 of them in the United States, roughly 6,000 of them working in manufacturing and 2,000 in research and development.

Zimmer Biomet Holdings, Inc.

Zimmer Biomet designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic products; bone cement; surgical products; and integrated digital and robotic technologies, all for patients with disorders of, or injuries to, bones, joints or supporting soft tissues. Zimmer Biomet Holdings was incorporated in Delaware in 2001, though the history runs back to 1927 and predecessor Zimmer Manufacturing Company in Warsaw, Indiana. It was spun off from its former parent on 6 August 2001, and in 2015 acquired the parent of Biomet and changed its name from Zimmer Holdings. There were approximately 17,000 employees worldwide at the end of 2025, about 7,000 of them in the United States, roughly 6,000 of them working in manufacturing and 2,000 in research and development.

Knees

A total knee replacement typically uses a femoral component, a patella, a tibial tray and an articular surface on the tray, split between first-time replacements and revisions of an implant from an earlier operation. Partial reconstructions treat limited degeneration by replacing only one compartment with a unicompartmental prosthesis. The main brands are the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. The ROSA Robot assists a surgeon with implant positioning in both total and partial knee arthroplasty.

Hips

A total hip replacement replaces both the head of the femur and the socket of the pelvis, again split between first-time and revision procedures. Components are either attached with bone cement or press-fit into bone, their surface letting bone affix through ongrowth or ingrowth technologies. The main brands are the Taperloc Hip System, Avenir Complete Hip System, Z1 Hip Implant, Arcos Modular Hip System and G7 Acetabular System, and the ROSA Robot is used in hip procedures too.

S.E.T.

This category bundles sports medicine, biologics, foot and ankle, upper extremities, trauma and craniomaxillofacial and thoracic products. The 2025 mix within it was upper extremities 30 percent of the category's net sales, craniomaxillofacial and thoracic 21 percent, trauma 20 percent, sports medicine 12 percent, foot and ankle 12 percent and biologics 5 percent. Sports medicine repairs soft tissue injuries, mostly knee and shoulder; biologics are early intervention for joint preservation or support during surgery; foot and ankle and upper extremities treat arthritic conditions and fractures; trauma products stabilise broken bones so the body can heal; and craniomaxillofacial and thoracic covers face and skull reconstruction plus products that stabilise the bones of the chest. The main brands include the JuggerKnot Soft Anchor System, Gel-One Cross-linked Hyaluronate, Gorilla Ankle Fracture Plating System, Comprehensive Shoulder, Natural Nail System and SternaLock System, and the ROSA Robot is used in shoulder procedures.

Technology, data, bone cement and surgical

These are marketed collectively as the ZBEdge Platform, which connects the robotic and digital technologies so data is collected before, during and after surgery and fed back to surgeons as insight for decisions on patient care. Bone cement assists implant fixation, and the company sells a range of cements plus the products for mixing and delivering them, alongside a portfolio of surgical solutions for healthcare institutions.

How it reaches the surgeon

Customers are orthopedic surgeons, neurosurgeons and other specialists, healthcare institutions, stocking distributors, healthcare dealers, and purchasing organisations acting as agents, ranging from large multinationals to independent clinicians. There are two selling channels: direct to healthcare institutions such as hospitals and ambulatory surgery centres, and through stocking distributors and dealers. With direct accounts and some dealers the inventory is consigned to sales agents or customers, and consignment sales were approximately 85 percent of net sales in 2025, with no individual customer more than 2 percent. Inventory sits in the company's own warehouses with title to consigned stock retained, so quantities are there when a procedure needs them. Because most sales happen at the time of an elective procedure there are generally no firm orders, and orders usually ship by expedited courier. The field organisation is a network of sales associates, managers and support staff, some employed or contracted by independent distributors and sales agencies.

Manufacturing

Products are made at various sites, with some manufacturing outsourced to qualified suppliers. The plants use a cellular production concept and a continuous improvement philosophy driven by Lean and Six Sigma, aimed at product quality, shorter lead times and capacity optimisation, and at several sites employees are cross-trained across a broad array of operations. Process changes named in the filing include computer-assisted robots and multi-axis grinders for precision polishing, automated manufacturing and inspection, in-sourcing of core products, and negotiated supplier cost reductions. All raw materials and selected components are bought from external suppliers, some from single sources for quality assurance, sole source availability, cost effectiveness or regulatory reasons.

From Zimmer Biomet's annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in Zimmer Biomet Holdings became

Latest results

Latest quarterQ3 FY2026ended 30 September 2026 · 10-Q filed 4 November 2026
Revenue
$2.1 billion
+3.1% on the year · -5.2% on the quarter
Q4 FY2024Q3 FY2026
Net income
$192 million
-17.0% on the year · -3.4% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$1.00
-13.8% on the year · -2.9% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 20 February 2026
Revenue
$8.2 billion
+7.2% on the year
FY2018FY2025
Net income
$705 million
-22.0% on the year
FY2018FY2025
Diluted EPS
$3.55
-19.9% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsZimmer Biomet Holdings (ZBH) reported revenue of $8.2 billion for fiscal 2025, the year ended 31 December 2025, up 7.2% on the year before. Net income was $705 million and diluted earnings per share $3.55. Revenue was $7.7 billion in fiscal 2024, $7.4 billion in fiscal 2023, $6.9 billion in fiscal 2022 and $6.8 billion in fiscal 2021. Net income in the same years was $904 million, $1.0 billion, $231 million and $402 million. Over the twelve months to 30 September 2026, Zimmer Biomet Holdings reported revenue of $8.6 billion and net income of $767 million. Revenue grew 6.1% a year, compounded, over the five years to fiscal 2025. Zimmer Biomet Holdings declared $0.96 a share in dividends over the last four quarters and had 189 million shares outstanding at the latest filed count. At 30 September 2026 it carried $7.5 billion of debt and $400 million of cash. At the close of 6 November 2026 the market cap of Zimmer Biomet Holdings was $20.0 billion, 26.7 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE6.0%
ROCE5.7%
Operating margin13.6%
Net margin9.0%
FCF margin19.2%
Interest covern/a
Debt to equity0.59x
Cash conversion2.46x
Share count, last 12 months-4.5%
Sales CAGR, 3 years5.9%
Profit CAGR, 3 years45.0%
EPS, TTM$3.95

At the close of 6 November 2026

Price$105.56
Market cap$20.0 billion
Stock P/E26.7x
Price to book1.6x
EV / EBITDA11.9x
Dividend yield0.9%
Market cap / sales2.3x
52-week high$110.08
52-week low$79.58
Price, 1 year19.3%
Price CAGR, 3 years-0.1%
Price CAGR, 5 years-5.1%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on long-term debt as Zimmer Biomet Holdings, Inc. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.
ZBHgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 * †Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue1,7771,6631,7821,6701,8251,8311,8701,7541,9401,8891,9421,8242,0231,9092,0772,0012,2442,0872,1772,063
Cost of revenue536500511488520501526519539512554539587550592559792576636594
Gross profit1,2411,1631,2711,1821,3051,3301,3441,2351,4011,3771,3881,2861,4361,3591,4851,4421,4511,5101,5421,468
Gross margin70%70%71%71%71%73%72%70%72%73%71%70%71%71%71%72%65%72%71%71%
R&D96.096.999.4102108110118117113108109112108111113116119103105106
SG&A805684695655727716726675722736737710747759815811872850899855
Operating income134198281245-28.3327330267354266351280389292300351154373326308
Operating margin8%12%16%15%-2%18%18%15%18%14%18%15%19%15%14%18%7%18%15%15%
Pre-tax income-83.9101200178-74.828727721928421530223028922922527998.0301255230
Tax raten/a28%23%-9%n/a19%24%26%-48%20%20%-8%17%20%32%17%-41%21%22%16%
Net income-84.014.2154194-130232210163419172243249240182153231139238198192
Net margin-5%1%9%12%-7%13%11%9%22%9%13%14%12%10%7%12%6%11%9%9%
Diluted EPS-$0.39$0.07$0.73$0.92-$0.62$1.11$1.00$0.77$2.01$0.84$1.18$1.23$1.20$0.91$0.77$1.16$0.70$1.22$1.03$1.00
Operating cash flow366n/an/an/an/a308348338588228369396506383378419517359448560
Capital expenditure63.136.440.947.263.446.797.384.362.855.152.744.551.544.650.155.074.836.354.275.8
Free cash flow303n/an/an/an/a261251253526173317351455338328364443323394484
Buybacksn/an/an/an/an/a26814.30.041011485.959672.22307.20.025025025178.5
Dividends paid50.250.250.350.350.450.350.350.150.249.449.449.248.047.847.547.547.546.946.545.8
Shares outstanding209m210m210m210m209m209m209m209m205m206m204m199m199m198m198m198m196m193m191m189m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2007FY2008FY2009FY2010FY2011FY2012 †FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018FY2019 †FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Revenue3,8984,1214,0954,2204,4524,4724,6234,6735,9987,6687,8037,9336,9616,1286,8276,9407,3947,6798,2328,570
Cost of revenue8769979911,0121,1221,1251,2671,2431,8012,3822,1332,2721,9441,8241,9602,0202,0842,1912,4942,599
Gross profit3,0223,1243,1053,2083,3303,3463,3373,4244,1975,2875,6705,6615,0174,3034,8674,9205,3105,4875,7385,972
Gross margin77.5%75.8%75.8%76.0%74.8%74.8%72.2%73.3%70.0%68.9%72.7%71.4%72.1%70.2%71.3%70.9%71.8%71.5%69.7%69.7%
Research and development183192205218238226203187269366370392394323436406459437458433
Selling, general and administrative1,5171,7041,7291,7571,8341,8071,7491,7512,2842,9453,1053,3792,8102,7132,8432,7622,8392,9303,2573,476
Operating income1,1281,0901,0199171,0241,0471,0691,03746782179933.81,11283.18606961,2781,2861,0981,161
Operating margin28.9%26.4%24.9%21.7%23.0%23.4%23.1%22.2%7.8%10.7%10.2%0.4%16.0%1.4%12.6%10.0%17.3%16.7%13.3%13.6%
Interest expensen/an/a22.460.255.372.970.163.1287358328n/an/an/an/an/an/an/an/an/a
Pre-tax income1,1321,1229988609799901,008939153400465-271880-1054994041,0671,037831884
Income tax3582722812632192372302207.095.0-1,349108-238-96.053.511242.2131126116
Effective tax rate31.6%24.3%28.1%30.6%22.4%24.0%22.8%23.4%4.6%23.8%-290.3%n/a-27.0%n/a10.7%27.8%4.0%12.7%15.1%13.1%
Net income7738497175977617557807201473061,814-3791,132-1394022311,024904705767
Net margin19.8%20.6%17.5%14.1%17.1%16.9%16.9%15.4%2.5%4.0%23.2%-4.8%16.3%-2.3%5.9%3.3%13.8%11.8%8.6%9.0%
Diluted EPS$3.26$3.72$3.32$2.97$4.03$4.29$4.54$4.19$0.77$1.51$8.90-$1.86$5.47-$0.67$1.91$1.10$4.88$4.43$3.55$3.95
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K8-K8-K8-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by product or service FY2016 to FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Knees2,7512,7342,7742,7812,3782,6482,7783,0383,1743,32240.4%
S.E.T1,6391,7021,4011,6521,5261,7281,6971,7531,8662,15026.1%
Hips1,8621,8721,9191,9321,7501,8561,8951,9671,9992,09425.4%
Technology & Data, Bone Cement and Surgicaln/an/an/an/an/an/a5706366406668.1%
Dental428419n/an/an/an/an/an/an/an/an/a
Dental, Spine & CMFTn/an/a1,175n/an/an/an/an/an/an/an/a
Other328319664596473596n/an/an/an/an/a
Spine and CMF661758n/an/an/an/an/an/an/an/an/a
KneesS.E.THipsTechnology & Data, Bone Cement and Surgical FY2022 to FY2025Other FY2016 to FY2021Dental, Spine & CMFT FY2018Spine and CMF FY2016 to FY2017Dental FY2016 to FY2017
7,803FY20176,960FY20196,827FY20217,394FY20238,232FY2025

$ million; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Revenue by region FY2016 to FY2025, 1 year left out

FY2016FY2017FY2018FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Americas3,9283,929n/a3,7004,1024,2964,6244,7955,14562.5%
EMEA1,5131,5231,6701,2371,4771,4561,5921,6911,82922.2%
Asia Pacific1,0961,1581,2631,1911,2481,1881,1781,1931,25815.3%
Americas and Global Businessesn/an/a5,000n/an/an/an/an/an/an/a
Immaterial Product Category Operating Segments1,1321,193n/an/an/an/an/an/an/an/a
Americas FY2016 to FY2025EMEAAsia PacificAmericas and Global Businesses FY2018Immaterial Product Category Operating Segments FY2016 to FY2017
7,668FY20167,933FY20186,827FY20217,394FY20238,232FY2025

$ million; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

First forecast against the result

Zimmer Biomet Holdings's sales growth at constant currency landed at or above the top of the range in 1, inside it in 2 and under it in 1 of the 4 years shown (FY2011 to FY2014).

−1.4FY2011−1.7FY2012+0.4FY2013−2.6FY2014
  • At or above the top of the range
  • Inside the range
  • Under the range

Each bar is the year's result against the top of its first forecast range, in percentage points. Hover a bar for the figures.

Fiscal yearFirst forecast
sales growth at constant currency		Result
FY20112% to 4%2.6%
FY20122% to 4%2.3%
FY20132.5% to 4.5%4.9%
FY20143% to 5%2.4%
First forecast
The full-year range the company gave with its fourth-quarter results for the year before, before any later change to it.
Result
The figure the company reported for that year with its next fourth-quarter results.
Years left out
Where the forecast or the result could not be read with confidence. Each figure in the table links to the results release it comes from.

Cash flow

FY2007FY2008FY2009FY2010FY2011FY2012 †FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018FY2019 †FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Operating cash flow1,0841,0381,1181,1941,1771,1529631,060n/a1,6321,5821,7471,5861,2041,4991,2851,5821,4991,6971,885
Capital expenditure19325010579.2114115100145168185156163198112144188291204224241
Free cash flow8927881,0121,1141,0631,037863916n/a1,4481,4261,5851,3871,0931,3561,0971,2901,2961,4731,644
Free cash flow margin22.9%19.1%24.7%26.4%23.9%23.2%18.7%19.6%n/a18.9%18.3%20.0%19.9%17.8%19.9%15.8%17.5%16.9%17.9%19.2%
Cash from investing-492-924-381-727-624-592-282n/an/a-1,692-511-417-729-614-504n/a-779-888-1,976-1,215
Cash from financing-400-344-262-490-456-436-467n/an/a-743-1,210-1,302-780-422-1,306n/a-764-484326-1,564
Depreciation and amortisation2302753373403603633583767121,0391,0631,0408718989389269529961,0941,107
Share-based compensation70.169.975.362.060.555.048.549.446.457.353.765.577.273.876.010599.810190.297.1
Buybacks5767379245061,050486721400150416n/an/an/an/an/a126692868487829
Dividends paidn/an/an/an/an/a94.4132146157188194195197198200201201196190187
Dividend per sharen/an/an/an/a$0.18$0.54$0.80$0.88$0.88$0.96$0.96$0.96$0.96$0.96$0.96$0.96$0.96$0.96$0.96n/a
Diluted shares, weighted238m228m216m201m189m176m172m172m190m202m204m204m207m207m210m210m210m204m199m191m
Shares outstanding at period endn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a189m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K8-K8-K8-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2007FY2008FY2009FY2010FY2011FY2012 †FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018FY2019 †FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Funded by
Shareholders' equity5,4525,6505,6395,7715,5075,8616,2976,5509,8889,66911,73611,27112,38812,19412,66112,02012,48012,46812,69812,716
Non-controlling interestn/a3.60.00.07.65.42.81.81.51.0-0.34.84.75.25.76.77.78.18.110.0
Short-term borrowingsn/an/an/a0.0n/an/a0.5n/an/an/an/an/an/an/an/an/an/an/an/an/a
Debtn/a4601,1281,1421,7191,8211,6721,42611,49711,24110,1428,9398,2008,1007,1005,7005,8006,2057,5197,504
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/an/a216165175167174190176n/a
Other liabilitiesn/a1,1251,0191,0861,2811,3251,6081,6815,7745,7734,0863,9123,8303,9533,5153,1723,0342,4942,6913,309
Total liabilities and equityn/a7,2397,7868,0008,5159,0129,5819,65827,16126,68425,96424,12724,63924,41823,45621,06621,49721,36523,09223,539
Owned
Fixed assetsn/a1,2641,2221,2141,2071,2111,2301,2852,0632,0382,0392,0152,0771,8641,8371,8722,0602,0492,2072,310
Goodwilln/a2,7752,7842,5812,6262,5722,6112,5149,93410,64410,6689,5949,1978,9838,9198,5808,8188,9519,94710,336
Intangible assetsn/a8728588277987417086048,7468,7858,3537,6857,2586,1645,5345,0644,8564,5984,7174,635
Investmentsn/an/a66.4265456672727612165n/an/an/an/an/an/an/an/an/an/an/a
Cash and equivalents4642136926697688841,0811,0831,459634524543618775378376416526592400
Receivablesn/a7337517768398859379121,4461,6041,5441,2761,3641,2781,2601,3821,4421,4811,7041,816
Inventoryn/a9289139369309951,0741,1932,2541,9592,0682,2562,3852,1742,1482,1472,3852,2352,2862,367
Other assetsn/a4545007328911,0531,2141,4541,0931,0197677571,7403,1793,3811,6451,5181,5261,6381,675
Total assetsn/a7,2397,7868,0008,5159,0129,5819,65827,16126,68425,96424,12724,63924,41823,45621,06621,49721,36523,09223,539
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K8-K8-K8-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded3.2%6.1%5.9%7.0%
Profit growth, compounded17.0%n/a45.0%-4.7%
Return on equity, average4.9%5.2%7.0%5.6%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Zimmer Biomet Holdings' revenue in fiscal 2025?

Zimmer Biomet Holdings (ZBH) reported revenue of $8.2 billion for fiscal 2025, the year ended 31 December 2025, up 7.2% on the year before.

How much did Zimmer Biomet Holdings earn in fiscal 2025?

Net income was $705 million for fiscal 2025, and diluted earnings per share $3.55.

What is Zimmer Biomet Holdings' P/E ratio?

At the close of 6 November 2026, Zimmer Biomet Holdings traded at 26.7 times its earnings over the twelve months to 30 September 2026.

What is Zimmer Biomet Holdings' market cap?

The market cap of Zimmer Biomet Holdings was $20.0 billion at the close of 6 November 2026.

Does Zimmer Biomet Holdings pay a dividend?

Yes. Zimmer Biomet Holdings declared $0.96 a share in dividends over the four quarters to 30 September 2026.

Peers: Medical Equipment

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Intuitive Surgical Inc. ISRG$156.9 billion54.7518.5%28.4%20.5%0.00n/a
Edwards Lifesciences Corp. EW$58.8 billion57.679.4%21.6%13.4%0.06n/a
Steris plc STE$24.5 billion29.9311.4%19.0%8.1%0.261.0%
Zimmer Biomet Holdings, Inc. ZBH$20.0 billion26.736.0%13.6%7.0%0.590.9%
Smith & Nephew plc SNN *$13.7 billion21.7611.8%12.9%6.1%0.592.4%
Align Technology Inc. ALGN$11.7 billion24.1711.4%14.9%4.4%0.00n/a
MSA Safety Inc. MSA$6.6 billion21.8621.1%20.2%8.1%0.781.3%
Establishment Labs Holdings Inc. ESTA$2.0 billionn/a-246.6%-6.6%38.3%17.17n/a
Enovis Corp. ENOV$1.6 billionn/a-35.3%-20.6%3.3%0.84n/a
Cadre Holdings, Inc. CDRE$1.4 billion34.4211.2%10.7%18.3%1.011.2%
Anteris Technologies Global Corp. AVR$553 millionn/a-41.2%-4,738.4%-9.6%0.00n/a
Sanara MedTech Inc. SMTI$291 millionn/a-403.0%n/a12.9%5.85n/a
All 110 in Medical Equipment
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Intuitive Surgical Inc. ISRG$156.9 billion54.7518.5%28.4%20.5%0.00n/a
Medtronic plc MDT$130.3 billion25.0710.4%18.1%9.8%0.562.8%
Stryker Corp. SYK$124.0 billion34.7015.4%20.7%7.9%0.641.1%
3M Co. MMM$95.7 billion27.6185.7%18.8%1.7%3.631.7%
Boston Scientific Corp. BSX$62.0 billion18.1113.7%18.7%8.9%0.47n/a
Edwards Lifesciences Corp. EW$58.8 billion57.679.4%21.6%13.4%0.06n/a
Becton Dickinson & Co. BDX$57.7 billion63.803.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$52.2 billion57.614.9%5.7%n/a1.07n/a
GE HealthCare Technologies Inc. GEHC$37.2 billion17.3818.5%13.3%6.9%0.860.2%
Resmed Inc. RMD$33.1 billion21.4226.8%33.0%9.0%0.071.0%
Dexcom Inc. DXCM$29.6 billion31.1439.1%24.0%13.0%0.49n/a
Koninklijke Philips N.V. PHG *$29.2 billion29.228.2%8.0%-1.0%0.741.3%
West Pharmaceutical Services Inc. WST$27.9 billion44.8721.5%23.0%12.6%0.070.2%
Steris plc STE$24.5 billion29.9311.4%19.0%8.1%0.261.0%
Zimmer Biomet Holdings, Inc. ZBH$20.0 billion26.736.0%13.6%7.0%0.590.9%
Solventum Corp. SOLV$15.4 billion101.513.2%5.6%-2.8%1.05n/a
Smith & Nephew plc SNN *$13.7 billion21.7611.8%12.9%6.1%0.592.4%
Baxter International Inc. BAX$13.3 billionn/a-11.1%-1.9%5.3%1.322.0%
Glaukos Corp. GKOS$13.3 billionn/a-23.7%-25.5%46.9%0.00n/a
Penumbra Inc. PEN$12.6 billion80.459.9%12.1%17.0%0.00n/a
Cooper Companies, Inc. COO$11.9 billion21.296.8%12.8%4.7%0.31n/a
Align Technology Inc. ALGN$11.7 billion24.1711.4%14.9%4.4%0.00n/a
Insulet Corp. PODD$10.2 billion23.8727.2%18.4%26.5%0.61n/a
Globus Medical Inc. GMED$9.5 billion17.4511.6%21.6%13.4%0.00n/a
Bausch & Lomb Corp. BLCO$7.1 billionn/a-1.7%7.1%8.9%0.79n/a
MSA Safety Inc. MSA$6.6 billion21.8621.1%20.2%8.1%0.781.3%
Teleflex Inc. TFX$6.0 billion18.338.7%9.4%20.9%0.460.9%
Haemonetics Corp. HAE$5.5 billion53.8311.6%12.8%4.1%1.26n/a
Merit Medical Systems Inc. MMSI$5.2 billion32.809.2%13.5%9.1%0.42n/a
LivaNova plc LIVN$5.0 billion30.0114.3%10.7%11.7%0.22n/a
MiniMed Group, Inc. MMED$4.7 billionn/an/an/an/a0.00n/a
Heartflow, Inc. HTFL$4.5 billionn/a-42.3%-37.8%n/a0.00n/a
Integer Holdings Corp. ITGR$4.3 billion42.486.0%8.2%-0.3%0.71n/a
ICU Medical Inc. ICUI$4.3 billion71.992.8%5.1%-5.9%0.53n/a
Envista Holdings Corp. NVST$4.0 billion6.5120.5%25.4%9.8%0.46n/a
Pulse Biosciences, Inc. PLSE$3.9 billionn/a-45.6%-5,821.1%1,637.2%0.00n/a
Warby Parker Inc. WRBY$3.2 billion424.581.9%0.2%9.9%0.00n/a
TransMedics Group, Inc. TMDX$3.1 billion23.8926.2%11.9%28.5%0.930.0%
iRhythm Holdings, Inc. IRTC$3.0 billionn/a-21.8%-5.7%21.6%3.68n/a
Axogen, Inc. AXGN$3.0 billionn/a-6.4%-5.2%24.3%0.00n/a
AtriCure, Inc. ATRC$3.0 billion195.032.8%2.9%13.8%0.11n/a
UFP Technologies Inc. UFPT$2.3 billion30.9015.8%15.5%8.6%0.20n/a
Establishment Labs Holdings Inc. ESTA$2.0 billionn/a-246.6%-6.6%38.3%17.17n/a
Dentsply Sirona Inc. XRAY$1.9 billionn/a-8.9%-1.5%-1.4%1.626.8%
Lemaitre Vascular Inc. LMAT$1.9 billion29.4214.7%27.7%11.8%0.391.2%
Inspire Medical Systems, Inc. INSP$1.8 billion18.5712.2%1.8%-0.2%0.00n/a
Kestra Medical Technologies, Ltd. KMTS$1.7 billionn/a-67.4%-134.5%60.7%0.33n/a
Butterfly Network, Inc. BFLY$1.7 billionn/a-29.1%-46.9%39.3%0.000.0%
Enovis Corp. ENOV$1.6 billionn/a-35.3%-20.6%3.3%0.84n/a
NovoCure Ltd. NVCR$1.6 billionn/a-34.7%-17.2%12.9%0.56n/a
Conmed Corp. CNMD$1.5 billion21.306.9%9.9%1.6%0.771.2%
National Vision Holdings, Inc. EYE$1.4 billion29.335.6%4.1%7.8%0.26n/a
Cadre Holdings, Inc. CDRE$1.4 billion34.4211.2%10.7%18.3%1.011.2%
Staar Surgical Co. STAA$1.3 billion1,815,851,369,755,783,936.000.1%0.2%42.4%0.00n/a
Procept BioRobotics Corp. PRCT$1.2 billionn/a-34.9%-33.6%17.5%0.16n/a
Tandem Diabetes Care Inc. TNDM$1.2 billionn/a-36.4%-2.4%6.8%4.47n/a
Alphatec Holdings, Inc. ATEC$1.2 billionn/an/a-3.6%15.3%n/an/a
Iradimed Corp. IRMD$1.1 billion46.1422.5%32.3%11.0%0.000.9%
Si-Bone, Inc. SIBN$1.1 billionn/a-7.4%-7.6%14.0%0.190.0%
Integra LifeSciences Holdings Corp. IART$1.0 billion78.971.2%4.4%0.8%1.71n/a
Ceribell, Inc. CBLL$1.0 billionn/a-62.9%-69.8%31.3%0.17n/a
Artivion, Inc. AORT$986 millionn/a-3.9%2.3%14.0%0.81n/a
Bioventus Inc. BVS$893 million13.2523.8%9.7%3.9%0.96n/a
Beta Bionics, Inc. BBNX$855 millionn/a-20.7%-72.7%43.7%0.00n/a
Orthopediatrics Corp. KIDS$828 millionn/a-10.0%-9.4%16.1%0.31n/a
Tactile Systems Technology Inc. TCMD$585 million25.2610.5%9.4%14.4%0.00n/a
Sight Sciences, Inc. SGHT$558 millionn/a-57.8%-29.5%16.2%0.83n/a
Anteris Technologies Global Corp. AVR$553 millionn/a-41.2%-4,738.4%-9.6%0.00n/a
Delcath Systems, Inc. DCTH$517 million1,494.000.4%-1.9%35.8%0.00n/a
Avita Medical, Inc. RCEL$513 millionn/an/a-33.9%17.0%n/an/a
Angiodynamics Inc. ANGO$497 millionn/a-20.1%-11.2%8.2%0.00n/a
Mimedx Group, Inc. MDXG$482 millionn/a-9.1%-8.3%-22.8%0.00n/a
SS Innovations International, Inc. SSII$430 millionn/a-23.3%-15.8%89.7%0.00n/a
NeuroPace Inc. NPCE$428 millionn/a-160.9%-15.3%11.6%4.970.0%
Shoulder Innovations, Inc. SI$426 millionn/a-28.2%-54.4%n/a0.13n/a
Cerus Corp. CERS$407 millionn/a-9.7%-1.0%n/a0.84n/a
Carlsmed, Inc. CARL$395 millionn/a-43.1%-61.1%n/a0.18n/a
Mobia Medical, Inc. MOBI$372 millionn/an/an/an/a0.05n/a
Embecta Corp. EMBC$350 million4.18n/a21.9%-7.6%n/a7.4%
Orchestra BioMed Holdings, Inc. OBIO$341 millionn/a-305.5%-181.4%986.1%1.80n/a
Orthofix Medical Inc. OFIX$320 millionn/a-14.4%-4.7%3.0%0.52n/a
CapsoVision, Inc. CV$316 millionn/a-226.6%-217.1%n/a0.00n/a
Cytosorbents Corp. CTSO$308 millionn/an/a-34.7%3.1%n/an/a
Sanara MedTech Inc. SMTI$291 millionn/a-403.0%n/a12.9%5.85n/a
ClearPoint Neuro, Inc. CLPT$276 millionn/a-132.5%-70.6%32.5%1.86n/a
InfuSystem Holdings, Inc. INFU$272 million33.3414.4%9.3%2.5%0.35n/a
Treace Medical Concepts, Inc. TMCI$265 millionn/a-90.5%-24.4%-7.1%0.91n/a
Profound Medical Corp. PROF$264 millionn/a-76.4%-145.1%65.3%0.11n/a
Orasure Technologies Inc. OSUR$238 millionn/a-15.5%-48.1%-18.9%0.00n/a
Utah Medical Products Inc. UTMD$231 million22.138.6%28.4%-7.0%0.00n/a
Electromed, Inc. ELMD$226 million20.5820.9%18.8%15.3%0.00n/a
PRO DEX Inc. PDEX$202 million17.3524.4%16.8%13.3%0.33n/a
TriSalus Life Sciences, Inc. TLSI$200 millionn/a-430.7%-67.7%25.2%5.05n/a
Anika Therapeutics, Inc. ANIK$195 millionn/a-1.3%-2.1%9.4%0.00n/a
RxSight, Inc. RXST$190 millionn/a-20.9%-50.4%-14.3%0.00n/a
Inogen Inc. INGN$161 millionn/a-14.1%-8.7%3.2%0.00n/a
Edap TMS SA FOCL$158 millionn/a-104.3%-35.4%n/a0.99n/a
Koru Medical Systems, Inc. KRMD$143 millionn/a-10.1%-3.7%22.4%0.00n/a
Apyx Medical Corp. APYX$124 millionn/a-87.6%-5.5%24.4%3.89n/a
Pulmonx Corp. LUNG$112 millionn/a-124.4%-44.4%-3.2%1.11n/a
Stereotaxis, Inc. STXS$111 millionn/a-182.3%-75.7%-5.5%0.00n/a
SkinHealth Systems Inc. SKIN$102 millionn/a-32.8%2.4%-4.4%4.36n/a
Lakeland Industries Inc. LAKE$88 millionn/a-21.4%-4.1%-0.4%0.23n/a
Outset Medical, Inc. OM$79 millionn/a-85.4%-51.2%1.6%1.18n/a
Neuraxis, Inc. NRXS$77 millionn/a-114.0%-144.5%65.2%0.01n/a
Lucid Diagnostics Inc. LUCD$76 millionn/a-478.3%-930.8%24.9%2.15n/a
Lensar, Inc. LNSR$66 millionn/a232.8%-13.5%3.3%0.25n/a
NutriBand Inc. NTRB$66 millionn/a-130.7%-435.6%-37.3%0.00n/a
RenovoRx, Inc. RNXT$55 millionn/a-140.2%-489.0%n/a0.00n/a
PAVmed Inc. PAVM$10 millionn/a-34.5%-23,841.1%-89.0%0.43n/a
14 companies share its SEC industry code (Orthopedic, Prosthetic & Surgical Appliances & Supplies); the rest are the names nearest in size in its wider industry, Medical Equipment, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on ZBH

Dividends$0.96 a share over the four quarters to 30 September 2026, a 0.91% yield
Filings19 in twelve months: 11 current reports (8-K), about 4 results of operations; 3 officer or director change; 3 regulation FD disclosure; 1 other events; 1 material agreement
Planned insider sales9 Form 144 notices in twelve months, $5.8 million; latest 11 September 2026
Options tapeput/call 1.18 by open interest at the 6 November 2026 close; the straddle prices a 4.7% move to 20 November 2026
13F holders916 funds reported a position for the quarter to 30 June 2026; largest Dodge & Cox
Insider trading6 sales and 0 purchases on Form 4 in twelve months
Congress0 House trades disclosed in six months
Short interest8.0 million shares short, 3.94 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 20264 November 2026EDGAR
10-Q30 June 20265 August 2026EDGAR
10-Q31 March 20261 May 2026EDGAR
10-K31 December 202520 February 2026EDGAR
10-Q30 September 20255 November 2025EDGAR
10-Q30 June 20257 August 2025EDGAR
10-Q31 March 20255 May 2025EDGAR
10-K31 December 202425 February 2025EDGAR
10-Q30 September 202430 October 2024EDGAR
10-Q30 June 20247 August 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.